Keywords
Chronic kidney disease
dyslipidemia
triglycerides
high density lipoprotein
glomerular filtration rate
incidence
association
cardiovascular disease
cohort
Colombia
dyslipidemia
triglycerides
high density lipoprotein
glomerular filtration rate
incidence
association
cardiovascular disease
cohort
Colombia
How to Cite
Becerra-Arias, C., Vera-Cala, L. M., & Fernández-Niño, J. A. (2019). Association between Tg/HDL ratio and Chronic Kidney Disease in a colombian cohort. Salud UIS, 51(4), 321–331. https://doi.org/10.18273/revsal.v51n4-2019005
Abstract
Introduction: Chronic Kidney Disease (CKD) has a strong impact on global public health. This is due to the high risk of cardiovascular disease in those who suffer from it. The triglycerides / high density lipoprotein ratio has been associated with the development and progression of kidney disease. Objective: To estimate the association between the ratio triglycerides / high density lipoprotein and the incidence of kidney disease in a Colombian cohort. Methodology: Prospective cohort study of the follow-up of INEFAC 2007-2017, with 1626 participants. The main exposure was determined as a cut-off point> 3.75 in the ratio. The cases were defined as having an estimated glomerular filtration rate <60ml / min / 1.73m2 or previous medical diagnosis. Linear regression and log-binomial models were adjusted for changes in the estimated rate and incidence of chronic kidney disease. As covariates: age, sex, race, alcohol, cigarette, waist circumference, and physical activity. Results: The incidence of kidney disease was 0.4% (95% CI: 0.1-0.8), the average of the estimated rate was 94.3ml / min / 1.73m2. The association between the ratio triglycerides / high density lipoprotein and chronic kidney disease was not statistically significant in the unadjusted model (RR = 2.3, 95% CI: 0.5-9.4) nor in the adjusted by confounders (RR = 1.1, 95% CI: 0.2-5.6). Conclusion: It was not possible to determine the explored association, probably because it does not exist in the studied population or because a higher sample size is required, due to the low number of events.
References
1. Levey AS, Atkins R, Coresh J, Cohen EP, Collins AJ, Eckardt K-U, et al. Chronic kidney disease as a global public health problem: approaches and initiatives - a position statement from kidney disease improving global outcomes. Kidney Int. 2007; 72(3): 247-259. doi: http://dx.doi.org/doi:10.1038/sj.ki.5002343.
2. Cusumano AM, González BM. Chronic kidney disease in Latin America: Time to improve screening and detection. Clin J Am Soc Nephrol. 2008; 3(2): 594-600. doi: http://dx.doi.org/doi:10.2215/CJN.03420807.
3. Tsimihodimos V, Mitrogianni Z, Elisaf M. Dyslipidemia associated with chronic kidney disease. Open Cardiovasc Med J. 2011; 5(Vldl): 41-48. doi: http://dx.doi.org/doi:10.2174/187419240110501 0041.
4. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Circ Cardiovasc Interv. 2003; 108: 2154-2169. doi: http://dx.doi. org/doi:10.1161/01.CIR.0000095676.90936.80.
5. Thomas R, Kanso A, Sedor JR. Chronic kidney disease and its complications. Prim Care. 2008; 35(2): 329-344. doi: http://dx.doi.org/doi:10.1016/j.pop.2008.01.008.
6. Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, et al. Chronic kidney disease: global dimension and perspectives. Lancet. 2013; 382(13): 260-272. doi: http://dx.doi.org/doi:10.1016/S0140-6736(13)60687-X.
7. Cuenta de Alto Costo. Boletín de información técnica especializada. 2018.
8. Fondo colombiano de enfermedades de alto costo. Situación de la enfermedad renal en Colombia 2015.
9. Wang F, Ye P, Luo L, Xiao W, Wu H. Association of risk factors for cardiovascular disease and glomerular filtration rate: a community-based study of 4925 adults in Beijing. Nephrol Dial Transplant. 2010; 25: 3924-3931. doi: http://dx.doi.org/doi:10.1093/ndt/gfq327.
10. Tsuruya K, Yoshida H, Nagata M, Kitazono T, Hirakata H, Iseki K, et al. Association of the triglycerides to high-density lipoprotein cholesterol ratio with the risk of chronic kidney disease: analysis in a large Japanese population. Atherosclerosis. Elsevier Ltd. 2014; 233(1): 260–267. doi: http://dx.doi.org/doi:10.1016/j. atherosclerosis.2013.12.037
11. Hou X, Wang C, Zhang X, Zhao X, Wang Y, Li C, et al. Triglyceride levels are closely associated with mild declines in estimated glomerular filtration rates in middle-aged and elderly Chinese with normal serum lipid levels. PLoS One. 2014; 9(9): e106778. doi: http:// dx.doi.org/doi:10.1371/journal.pone.0106778.
12. Muntner P, Coresh J, Smith C, Eckfeldt J, Klag M. Plasma lipids and risk of developing renal dysfunction: The atherosclerosis risk in communities study. Kidney Int Suppl. 2000; 58: 293-301.
13. De Boer IH, Astor BC, Kramer H, Palmas W, Seliger SL, Shlipak MG, et al. Lipoprotein abnormalities associated with mild impairment of kidney function in the multi-ethnic study of atherosclerosis. Clin J Am Soc Nephrol. 2008; 3(1): 125-132. doi: http://dx.doi.org/doi:10.2215/CJN.03390807.
14. Chan CM. Hyperlipidaemia in chronic kidney disease. Ann Acad Med Singapore. 2005; 34(1): 31-35.
15. Vaziri ND. Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. Am J Physiol Renal Physiol. 2019; 290(2): F262-F272. doi: https://doi.org/10.1152/ ajprenal.00099.2005.
16. Lodh M, Lal S, Goswami B, Karmakar P, Parida AK. Dyslipidemia in chronic renal failure: ¿Cause or effect? Asian J Med Sci. 2016; 7(5): 42-46. doi: http://dx.doi.org/doi:10.3126/ajms.v7i5.14755.
17. Tsuruya K, Kitazono T, Yoshida H, Iseki K, Nagata M, Iseki C, et al. Impact of the triglycerides to high-density lipoprotein cholesterol ratio on the incidence and progression of CKD: a longitudinal study in a large Japanese population. Am J Kidney Dis. 2015; 66(6): 972-983. doi: http://dx.doi.org/doi:10.1053/j.ajkd.2015.05.011.
18. Sonmez A, Yilmaz MI, Saglam M, Unal HU, Hakki MG, Karaman C, et al. The role of plasma triglyceride/high-density lipoprotein cholesterol ratio to predict cardiovascular outcomes in chronic kidney disease. Lipids in Health and Disease. 2015; 14:29. doi: https://doi.org/10.1186/s12944-015-0031-4.
19. Mänttäri M, Tiula E, Alikoski T, Manninen V. Effects of hypertension and dyslipidemia on the decline in renal function. Hypertension.1995; 26: 670-675. doi: http://dx.doi.org/doi:10.1161/01. HYP.26.4.670.
20. Aljabri KS, Bokhari SA, Alshareef MA, Khan PM, AbuElsaoud HM, Jalal MM, et al. Serum lipid profiles in patients with chronic kidney disease in a Saudi population. Endocrinol Metab Int J. 2019; 7(1): 41-46.
21. Bautista LE, Orostegui M, Vera LM, Prada GE, Orozco LC, Herrán OF. Prevalence and impact of cardiovascular risk factors in Bucaramanga, Colombia: results from the Countrywide Integrated Noncommunicable Disease Intervention Programme (CINDI / CARMEN) baseline survey. Eur J Cardiovasc Prev Rehabil. 2006; 13: 769-775.
22. Fukuyama N, Homma K, Wakana N, Kudo K, Suyama A, Ohazama H, et al. Validation of the Friedewald equation for evaluation of plasma LDL-Cholesterol. J Clin Biochem Nutr. 2008; 43(1): 1-5. doi: http://dx.doi.org/doi:10.3164/ jcbn.2008036.
23. American academy of family physicians. practice guidelines: New AHA Recommendations for blood pressure measurement - FP Essent. 2005.
24. Martínez A, Górriz JL, Bover J, Segura-de la Morena J, Cebollada J, Escalada J, et al. Documento de consenso para la detección y manejo de la enfermedad renal crónica. Atención Prim. 2014; 46(9): 501-519. doi: http://dx.doi.org/doi:10.1016/j.aprim.2014.09.002.
25. National Institutes of Health. third report of the national cholesterol education program. detection, evaluation and treatment of high blood cholesterol in adults (adults treatment panel III). 1991; 151(6): 1-284.
26. Kang HT, Shim JY, Lee YJ, Lee JE, Linton JA, Kim JK, et al. Association between the ratio of triglycerides to high-density lipoprotein cholesterol and chronic kidney disease in Korean adults: the 2005 Korean National Health and Nutrition Examination Survey. Kidney Blood Press Res. 2011; 34(3): 173-179. doi: http://dx.doi. org/doi:10.1159/000323895.
27. Kim JY, Kang HT, Lee HR, Lee YJ, Shim JY. Comparison of lipid-related ratios for prediction of chronic kidney disease stage 3 or more in korean adults. J Korean Med Sci. 2012; 27(12): 1524-1529. doi: http://dx.doi.org/10.3346/jkms.2012.27.12.1524.
28. Sauer B, Brookhart MA, Roy JA, VanderWeele TJ. Covariate Selection. In: Velentgas P, Dreyer NA, Nourjah P, Smith ST, Marion M. Torchia editors. Developing a protocol for observational comparative effectiveness research: a user´s guide. Rockville: agency for healthcare research and quality; 2013.p. 1-32.
29. Wang F, Zheng J, Ye P, Luo L, Bai Y, Xu R, et al. Association of High-Density lipoprotein cholesterol with the estimated glomerular filtration rate in a community-based population. Plos One. 2013; 8(11): e79738. doi: http://dx.doi.org/doi:10.1371/journal.pone.0079738.
30. Ji B, Zhang S, Gong L, Wang Z, Ren W, Li Q, et al. The risk factors of mild decline in estimated glomerular filtration rate in a community-based population. Clin Biochem. 2013; 46: 750-754. doi: http://dx.doi.org/10.1016/j. clinbiochem.2013.01.011.
31. Yang T, Chu CH, Hsu CH, Hsieh PC, Chung TC, Bay CH, et al. Impact of metabolic syndrome on the incidence of chronic kidney disease: A Chinese cohort study. Nephrology. 2012; 17: 532- 538. doi: http://dx.doi.org/doi:10.1111/j.1440- 1797.2012.01607.x.
32. Vargas-Uricoechea H, Casas-Figueroa LA. Epidemiología de la diabetes mellitus en Sudamérica: la experiencia de Colombia. Clin Investig Arterioscler. 2016; 28(5): 245-256. doi: http://dx.doi.org/10.1016/j.arteri.2015.12.002.
33. Ramachandran A, Snehalatha C, Shetty AS, Nanditha A. Trends in prevalence of diabetes in Asian countries. World J Diabetes. 2012; 3(6): 110-117. doi: http://dx.doi.org/doi:10.4239/wjd. v3.i6.110.
34. Liu Y, Zhou D, Zhang Z, Song Y, Zhang D, Zhao T, et al. Effects of genetic variants on lipid parameters and dyslipidemia in a Chinese population. J Lipid Res. 2011; 52(2): 354-360. doi: http://dx.doi.org/ doi:10.1194/jlr.P007476.
35. Peralta CA, Shlipak MG, Fan D, Ordoñez J,Lash JP, Chertow GM, et al. Risks for end-stage renal disease, cardiovascular events, and death in Hispanic versus Non-Hispanic white adults with chronic kidney disease. J Am Soc Nephrol. 2006; 17: 2892-2899. doi: http://dx.doi.org/doi:10.1681/ ASN.2005101122.
36. Fernández-Niño J. Comentario editorial. La importancia de publicar estudios con resultados “negativos”. Rev Univ Ind Santander Salud. 2016; 48(4): 467-468.
37. Bosques PF, Gómez AD. El sesgo de publicación es un problema científico frecuente que tiene consecuencias éticas adversas [editorial]. Medicina Universitaria. 2009;11(42): 1-2.
2. Cusumano AM, González BM. Chronic kidney disease in Latin America: Time to improve screening and detection. Clin J Am Soc Nephrol. 2008; 3(2): 594-600. doi: http://dx.doi.org/doi:10.2215/CJN.03420807.
3. Tsimihodimos V, Mitrogianni Z, Elisaf M. Dyslipidemia associated with chronic kidney disease. Open Cardiovasc Med J. 2011; 5(Vldl): 41-48. doi: http://dx.doi.org/doi:10.2174/187419240110501 0041.
4. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Circ Cardiovasc Interv. 2003; 108: 2154-2169. doi: http://dx.doi. org/doi:10.1161/01.CIR.0000095676.90936.80.
5. Thomas R, Kanso A, Sedor JR. Chronic kidney disease and its complications. Prim Care. 2008; 35(2): 329-344. doi: http://dx.doi.org/doi:10.1016/j.pop.2008.01.008.
6. Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, et al. Chronic kidney disease: global dimension and perspectives. Lancet. 2013; 382(13): 260-272. doi: http://dx.doi.org/doi:10.1016/S0140-6736(13)60687-X.
7. Cuenta de Alto Costo. Boletín de información técnica especializada. 2018.
8. Fondo colombiano de enfermedades de alto costo. Situación de la enfermedad renal en Colombia 2015.
9. Wang F, Ye P, Luo L, Xiao W, Wu H. Association of risk factors for cardiovascular disease and glomerular filtration rate: a community-based study of 4925 adults in Beijing. Nephrol Dial Transplant. 2010; 25: 3924-3931. doi: http://dx.doi.org/doi:10.1093/ndt/gfq327.
10. Tsuruya K, Yoshida H, Nagata M, Kitazono T, Hirakata H, Iseki K, et al. Association of the triglycerides to high-density lipoprotein cholesterol ratio with the risk of chronic kidney disease: analysis in a large Japanese population. Atherosclerosis. Elsevier Ltd. 2014; 233(1): 260–267. doi: http://dx.doi.org/doi:10.1016/j. atherosclerosis.2013.12.037
11. Hou X, Wang C, Zhang X, Zhao X, Wang Y, Li C, et al. Triglyceride levels are closely associated with mild declines in estimated glomerular filtration rates in middle-aged and elderly Chinese with normal serum lipid levels. PLoS One. 2014; 9(9): e106778. doi: http:// dx.doi.org/doi:10.1371/journal.pone.0106778.
12. Muntner P, Coresh J, Smith C, Eckfeldt J, Klag M. Plasma lipids and risk of developing renal dysfunction: The atherosclerosis risk in communities study. Kidney Int Suppl. 2000; 58: 293-301.
13. De Boer IH, Astor BC, Kramer H, Palmas W, Seliger SL, Shlipak MG, et al. Lipoprotein abnormalities associated with mild impairment of kidney function in the multi-ethnic study of atherosclerosis. Clin J Am Soc Nephrol. 2008; 3(1): 125-132. doi: http://dx.doi.org/doi:10.2215/CJN.03390807.
14. Chan CM. Hyperlipidaemia in chronic kidney disease. Ann Acad Med Singapore. 2005; 34(1): 31-35.
15. Vaziri ND. Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. Am J Physiol Renal Physiol. 2019; 290(2): F262-F272. doi: https://doi.org/10.1152/ ajprenal.00099.2005.
16. Lodh M, Lal S, Goswami B, Karmakar P, Parida AK. Dyslipidemia in chronic renal failure: ¿Cause or effect? Asian J Med Sci. 2016; 7(5): 42-46. doi: http://dx.doi.org/doi:10.3126/ajms.v7i5.14755.
17. Tsuruya K, Kitazono T, Yoshida H, Iseki K, Nagata M, Iseki C, et al. Impact of the triglycerides to high-density lipoprotein cholesterol ratio on the incidence and progression of CKD: a longitudinal study in a large Japanese population. Am J Kidney Dis. 2015; 66(6): 972-983. doi: http://dx.doi.org/doi:10.1053/j.ajkd.2015.05.011.
18. Sonmez A, Yilmaz MI, Saglam M, Unal HU, Hakki MG, Karaman C, et al. The role of plasma triglyceride/high-density lipoprotein cholesterol ratio to predict cardiovascular outcomes in chronic kidney disease. Lipids in Health and Disease. 2015; 14:29. doi: https://doi.org/10.1186/s12944-015-0031-4.
19. Mänttäri M, Tiula E, Alikoski T, Manninen V. Effects of hypertension and dyslipidemia on the decline in renal function. Hypertension.1995; 26: 670-675. doi: http://dx.doi.org/doi:10.1161/01. HYP.26.4.670.
20. Aljabri KS, Bokhari SA, Alshareef MA, Khan PM, AbuElsaoud HM, Jalal MM, et al. Serum lipid profiles in patients with chronic kidney disease in a Saudi population. Endocrinol Metab Int J. 2019; 7(1): 41-46.
21. Bautista LE, Orostegui M, Vera LM, Prada GE, Orozco LC, Herrán OF. Prevalence and impact of cardiovascular risk factors in Bucaramanga, Colombia: results from the Countrywide Integrated Noncommunicable Disease Intervention Programme (CINDI / CARMEN) baseline survey. Eur J Cardiovasc Prev Rehabil. 2006; 13: 769-775.
22. Fukuyama N, Homma K, Wakana N, Kudo K, Suyama A, Ohazama H, et al. Validation of the Friedewald equation for evaluation of plasma LDL-Cholesterol. J Clin Biochem Nutr. 2008; 43(1): 1-5. doi: http://dx.doi.org/doi:10.3164/ jcbn.2008036.
23. American academy of family physicians. practice guidelines: New AHA Recommendations for blood pressure measurement - FP Essent. 2005.
24. Martínez A, Górriz JL, Bover J, Segura-de la Morena J, Cebollada J, Escalada J, et al. Documento de consenso para la detección y manejo de la enfermedad renal crónica. Atención Prim. 2014; 46(9): 501-519. doi: http://dx.doi.org/doi:10.1016/j.aprim.2014.09.002.
25. National Institutes of Health. third report of the national cholesterol education program. detection, evaluation and treatment of high blood cholesterol in adults (adults treatment panel III). 1991; 151(6): 1-284.
26. Kang HT, Shim JY, Lee YJ, Lee JE, Linton JA, Kim JK, et al. Association between the ratio of triglycerides to high-density lipoprotein cholesterol and chronic kidney disease in Korean adults: the 2005 Korean National Health and Nutrition Examination Survey. Kidney Blood Press Res. 2011; 34(3): 173-179. doi: http://dx.doi. org/doi:10.1159/000323895.
27. Kim JY, Kang HT, Lee HR, Lee YJ, Shim JY. Comparison of lipid-related ratios for prediction of chronic kidney disease stage 3 or more in korean adults. J Korean Med Sci. 2012; 27(12): 1524-1529. doi: http://dx.doi.org/10.3346/jkms.2012.27.12.1524.
28. Sauer B, Brookhart MA, Roy JA, VanderWeele TJ. Covariate Selection. In: Velentgas P, Dreyer NA, Nourjah P, Smith ST, Marion M. Torchia editors. Developing a protocol for observational comparative effectiveness research: a user´s guide. Rockville: agency for healthcare research and quality; 2013.p. 1-32.
29. Wang F, Zheng J, Ye P, Luo L, Bai Y, Xu R, et al. Association of High-Density lipoprotein cholesterol with the estimated glomerular filtration rate in a community-based population. Plos One. 2013; 8(11): e79738. doi: http://dx.doi.org/doi:10.1371/journal.pone.0079738.
30. Ji B, Zhang S, Gong L, Wang Z, Ren W, Li Q, et al. The risk factors of mild decline in estimated glomerular filtration rate in a community-based population. Clin Biochem. 2013; 46: 750-754. doi: http://dx.doi.org/10.1016/j. clinbiochem.2013.01.011.
31. Yang T, Chu CH, Hsu CH, Hsieh PC, Chung TC, Bay CH, et al. Impact of metabolic syndrome on the incidence of chronic kidney disease: A Chinese cohort study. Nephrology. 2012; 17: 532- 538. doi: http://dx.doi.org/doi:10.1111/j.1440- 1797.2012.01607.x.
32. Vargas-Uricoechea H, Casas-Figueroa LA. Epidemiología de la diabetes mellitus en Sudamérica: la experiencia de Colombia. Clin Investig Arterioscler. 2016; 28(5): 245-256. doi: http://dx.doi.org/10.1016/j.arteri.2015.12.002.
33. Ramachandran A, Snehalatha C, Shetty AS, Nanditha A. Trends in prevalence of diabetes in Asian countries. World J Diabetes. 2012; 3(6): 110-117. doi: http://dx.doi.org/doi:10.4239/wjd. v3.i6.110.
34. Liu Y, Zhou D, Zhang Z, Song Y, Zhang D, Zhao T, et al. Effects of genetic variants on lipid parameters and dyslipidemia in a Chinese population. J Lipid Res. 2011; 52(2): 354-360. doi: http://dx.doi.org/ doi:10.1194/jlr.P007476.
35. Peralta CA, Shlipak MG, Fan D, Ordoñez J,Lash JP, Chertow GM, et al. Risks for end-stage renal disease, cardiovascular events, and death in Hispanic versus Non-Hispanic white adults with chronic kidney disease. J Am Soc Nephrol. 2006; 17: 2892-2899. doi: http://dx.doi.org/doi:10.1681/ ASN.2005101122.
36. Fernández-Niño J. Comentario editorial. La importancia de publicar estudios con resultados “negativos”. Rev Univ Ind Santander Salud. 2016; 48(4): 467-468.
37. Bosques PF, Gómez AD. El sesgo de publicación es un problema científico frecuente que tiene consecuencias éticas adversas [editorial]. Medicina Universitaria. 2009;11(42): 1-2.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Downloads
Download data is not yet available.